Eligo Bioscience

Eligo Bioscience is an antibiotic developer dedicated to treating microbiome precision and bacterial-related diseases. The company's antibiotics combine the CRISPR/Cas system with engineered phage capsids to develop antimicrobial agents that eradicate drug-resistant pathogens or toxic bacteria within the human microbiome, enabling customers to access next-generation antimicrobial drugs for treating diseases caused by superbugs.